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Abstract
Botulinum toxin injections are effective for hyperactivities of muscles and glands that
are  mediated  by  acetylcholine  (Ach)  release  in  neuronal  terminal.  The  effects  of
botulinum toxin are reversible because the involved nerves build new sprouts and
synapses with time. Thus, botulinum toxin is relatively safe and repeated applications
are needed. To maximize effects of botulinum toxin without side effects, understanding
the action mechanism of botulinum toxin and determining appropriate target sites are
very important. Many guidelines have already been published and provided useful
information for these. Therefore, in this chapter, we concentrate more on practical tips
for botulinum toxin injections.
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1. Introduction
The natural Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum, a type of
spore-producing gram-positive bacilli. Sources of botulism poisoning are soil, honey, canned
foods, etc., because C. botulinum thrives in anaerobic conditions. BoNT can be denatured at
over 80°C (176°F). BoNT consists of a heavy chain and light chain, which are polypeptides
linked by a disulfide bond [1]. Initially, the heavy chain binds to the surface of a nerve cell.
The light chain, which acts as a Zn-dependent protease, is internalized into the nerve cell, and
then, it cleaves specific soluble N-ethylmaleimide sensitive factor attachment protein receptor
(SNARE) proteins: synaptosome-associated protein (SNAP-25), syntaxin, and vesicle-associ-
ated membrane protein (VAMP). There are several serotypes of BoNT. Type A, C1, and E break
down SNAP-25; type C hydrolyzes syntaxin, and type B, D, F, and G block the function of
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VAMP. As a result, acetylcholine (Ach) remains inside the vesicles and cannot be released into
the synaptic cleft. The duration of the BoNT activity is generally limited to several weeks or
several months because the involved nerves form new sprouts and synapses that can release
Ach [2].
The first agent, which was approved by the Food and Drug Administration in 1989, is Botox®
(Allergan Inc, Irvine, CA, USA). Botulinum toxin type A (BoNT/A) is most commonly used
these days: Botox®, OnabotulinumtoxinA; Dysport®, AbobotulinumtoxinA; Xeomin®, Incobo-
tulinumtoxinA; Hengli/CBTX-A®, Chinese botulinumtoxin A; Neuronox/Meditoxin®, South
Korea botulinumtoxin A, etc. Botulinum toxin type B is also frequently used: Myobloc®/
Neurobloc®, RimabotulinumtoxinB.
The practitioners of BoNT injection need to remember that BoNT is a protein. This means that
BoNT can denature easily and contribute to the generation of neutralizing antibodies. BoNT
has to be stored at 2–8 °C (36–46 °F) and administrated only for a limited time [3–5]. Freezing,
light exposure, and shaking should be avoided. To reduce the incidence of antibody generation,
the following are recommended: maintain at least a 3-month interval between injections; use
the smallest possible dose, and avoid booster injections. Detailed prescription information for
widely used BoNTs is summarized in Table 1 [3–5].
Botox® [3] Dysport® [4] Myobloc® [5]
Contents OnabotulinumtoxinA AbobotulinumtoxinA RimabotulinumtoxinB
Human albumin Human albumin Human albumin
Sodium chloride Lactose Sodium succinate










4 hours, once diluted
Do not freeze Do not freeze




Provided as solution (pH 5.6)
Can be diluted with normal saline
Indications and
usage
Cervical dystonia Cervical dystonia Cervical dystonia
Blepharospasm Glabella lines
Spasticity in adult Upper limb spasticity in adult
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Allergy to cow’s milk protein
Limit of a total dose 400 Units 1000 Units NA
Minimal interval 3 months 12 weeks NA









Cautions Pregnancy (Category C)
Nursing mothers
Pediatric/geriatric use
Immunogenicity Positive antibodies: 0.0–1.2% Positive antibodies: 0.0–3.6% Neutralizing activity
Risk factors: frequent intervals,
higher doses
- 1 years: 10% (for 36% ELISA-
positive cases)
- 18 months: 18% (for 50% ELISA-
positive cases)
SNARE, soluble N-ethlymaleimide sensitive factor attachment protein receptor; SNAP-25, synaptosome-associated
protein; VAMP, vesicle-associated membrane protein; BoNT, botulinum neurotoxin; NA, not applicable.
*The incidence of antibodies are highly dependent on the methodology of the assay. Therefore, the simple comparisons
between different BoNTs are illogical.
Table 1. Summary of prescribing information.
Early BoNTs did not overcome the following problems: short-lasting effects, necrotizing
problem, and systematic toxicity [6]. However, there have been remarkable advances since
Scott et al. [7] successfully improved strabismus with purified BoNT injections. Now BoNT is
widely used to reduce the hyperactivity of muscles or glands mediated by Ach release [1]. For
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neurological disorders, BoNT can be effectively used for hyperkinetic movement disorders
(dystonia, hemifacial spasm, myoclonus, myokymia, tremor, etc.), spasticity, drooling, and
chronic migraines. Applications for strabismus, spasms of the gastrointestinal tract or genito-
urinary tract, and cosmetic work are possible.
In this chapter, although there have been many guidelines published, we focus more on the
practical tips for BoNT injections in the treatment of several neurological symptoms.
2. Before botulinum toxin injection
2.1. Selection of appropriate patients for botulinum toxin injections
The principle action mechanism of BoNT is to block the release of Ach from presynaptic nerve
terminals. Therefore, the Ach-mediated hyperactivities of muscles and glands could be good
targets for BoNT therapy. The following list shows representative indications for BoNT
injection.
• Hyperkinetic movement disorders
o Dystonia (cervical dystonia, blepharospasm, oro-mandibular dystonia, limb dystonia,
laryngeal dystonia, etc.)
o Hemifacial spasm
o Myoclonus, myokymia, tremor, dyskinesia, tics, etc.
• Other neurological disorders
o Spasticity





o Spasm or spasticity of the gastro-intestinal and genito-urinary tracts
o Cosmestic applications, etc.
The cautions and contraindications are as important as the proper indications. Patients with
neurological disorders involving anterior horn cells, peripheral nerves, neuro-muscular
junctions, and muscles require special care when injecting BoNT. Concomitant use of drugs,
which could affect neuro-muscular transmission or cause muscle weakness, is also not
recommended (Table 1) [3–5]. In addition, most BoNTs do not guarantee the safety of pregnant
women, nursing mothers, and pediatric patients. Hypersensitivities to any of the BoNTs or
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their components and the infection of target sites are important contraindications. Especial-
ly, Dysport® is contraindicated in patients with allergies to cow’s milk protein [4]. Anti-platelet
or anti-coagulation agents could cause a hematoma.
2.2. Selection of botulinum toxin
Despite past studies using different types of BoNT, it is unclear which one is the most effective
BoNT. Furthermore, it is generally accepted that the doses between different BoNT products
are not interchangeable [3–5, 8–10]. However, in real practice, patients who have been treated
with different BoNT products could visit your clinic any time. In this regard, a simple conver-
sion ratio between Botox® and Dysport® was made [11]. Based on the average recommended
dose of Dysport®(500 Units) and Botox® (200 Units) for patients with cervical dystonia, a
conversion ratio of 2.5:1 was assumed and it was found that Dysport® showed no inferiority
to Botox® at this ratio. The ratio of 2.5:1 has the practical advantage by simplifying the
interchanging process. This issue will be addressed in detail later.
3. Preparing botulinum toxin injection
3.1. Reconstitution
The widely used solvent for reconstituting BoNT is 0.9% normal saline. Hypotonic saline or
distilled water is not suitable as a solvent because it could cause pain. Recently one preliminary
study suggested that reconstituting BoNT with Ringer acetate could reduce the injection site
pain rather than with normal saline by normalizing the pH values of the solution [12].
Myobloc® is provided as a solution (pH 5.6) that can be used as is or diluted with normal saline
[5].
Regardless of the BoNT subtype, one unit of BoNT was defined as the calculated median
intraperitoneal lethal dose (LD50) in mice. However, the biological activity varies between
BoNTs. Although there is no consensus for the conversion ratio, we use the ratio of 2.5:1 for
Dysport® and Botox® because the non-inferiority of Dysport® has already been proven [11]. On
the assumption that the ratio of 2.5:1 is bioequivalent, the practitioner can make two kinds of
solutions (Table 2). To make a solution with a high concentration, 1 ml of 0.9% normal saline
is needed for 1 ample (100 Units) of Botox® and 2 ml of 0.9% normal saline for 1 ample (500
Units) of Dysport®. For a solution with a low concentration, 2 ml and 4 ml are mixed with 1
ample of Botox® and Dysport®, respectively. Then, the same volume of each solution indicates
the same potency (Table 2). It means that physicians do not need complicated calculations.
Because the same conversion ratio (2.5:1) is also applied to the limitations for the total doses
of Dysport® (1000 Units) and Botox® (400 Units), we believe that it is very simple and practical.
After injecting normal saline for reconstitution, the next step is to mix gently to minimize
unnecessary destruction of the toxin. Because the available time is short after reconstitution
What Practical Tips Can I Suggest during Botulinum Toxin Injection?
http://dx.doi.org/10.5772/64144
57
(within 24 hours for Botox® and Dysport®) [3, 4], it is more efficient to inject BoNT after gath-
ering sufficient numbers of patients who need BoNT treatment.
Botox®, OnabotulinumtoxinA Dysport®, AbobotulinumtoxinA
Units per 1 ample 100 Units 500 Units
Method #1 (high
concentration)
100 Units (1 ample): 1 ml of 0.9% N/S 500 Units (1 ample): 2 ml of 0.9% N/S
→ 0.1 ml solution = 10 Units of Ona-BoNT/A → 0.1 ml solution = 25 Units of Abo-BoNT/A
→ 0.01 ml solution = 1 Unit of Ona-BoNT/A → 0.01 ml solution = 2.5 Units of Abo-BoNT/A
Method #2 (low
concentration)
100 Units (1 ample): 2 ml of 0.9% N/S 500 Units (1 ample): 4 ml of 0.9% N/S
→ 0.1 ml solution = 5 Units of Ona-BoNT/A → 0.1 ml solution = 12.5 Units of Abo-BoNT/A
→ 0.01 ml solution = 0.5 Units of Ona-BoNT/A→ 0.01 ml solution = 1.25 Units of Abo-BoNT/A
BoNT/A, botulinum neurotoxin type A.
Table 2. Practical tips of conversion between Botox® and Dysport®.
3.2. Preparation of the syringe and needle
Generally, a 1-ml syringe, which can control the volume by 0.01 ml, is preferred. The practi-
tioner needs 0.03–0.05 ml more volume than the target volume, taking into consideration the
dead space inside of the needle. After the syringe is filled properly with the BoNT solution,
the practitioner should remove the air. The following are tips for removing air bubbles and
aligning the needle.
• Draw down the syringe quickly while holding the cap of syringe. It is based on the inertia
effect, and just one time is enough to collect bubbles on top. Tapping the body is also
available.
• Pull slightly back, before pushing forward, the plunger of the syringe. It will be helpful in
saving the BoNT in the dead space of the needle.
• Rotate the bevel of the needle in the same direction with the scale marks of the syringe.
The selection of the injection needle depends on the target sites. Because most facial muscles
are thin and close to the skin, a thin and short needle such as a 23- or 24-gauge needle is suitable
for the delivery of BoNT solution. In contrast, neck and limb muscles are thick, large, and
located relatively deep from skin. Thus, a thick and long needle such as a 21-gauge needle is
necessary.
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4. Injecting botulinum toxin
4.1. Determining target sites
BoNT injection is recommended for use in only limited areas. The reasons for the limited use
are because of the total dose and cost of BoNT. Therefore, determining the target is the most
important procedure in treatment with BoNT.
Determining target sites has the same meaning as finding symptomatic muscles. It is not
difficult to locate target sites for disorders with static muscular hypertonia (such as fixed
dystonia or spasticity). However, mobile hyperkinetic movement disorders are another matter.
Especially for mobile dystonia, finding target muscles is not simple because the direction of
abnormal movement seems to be irregular or changes every moment. Ultrasonography,
computed tomography, magnetic resonance imaging, and electromyography (EMG) are
supportive tools to help ascertain the target [13]. In particular, EMG can provide dynamic
information and help in the precise injection of BoNT to target muscles in real time. However
it should be kept in mind that EMG is not a substitute for knowledge of anatomy and is a mere
supportive tool. Another important thing is to avoid BoNT injections near sites where side
effects occur frequently. Particularly the procedure for head and neck requires special care.
Practical tips for examining patients and determining target sites are introduced below.
4.1.1. Cervical dystonia
The final posture of cervical dystonia (CD) patients consists of a combination of dystonic
muscle contractions, compensatory movements, and secondary musculo-skeletal changes.
Therefore, examination in various situations is helpful in differentiating target dystonic
muscles from the others.
Before the examination, enough exposure of the neck and adjacent muscles is very important.
This procedure is essential for precise inspection. In addition, sensory trick by scarf or clothes
could be eliminated. Then, the physicians should see the rotation and deviation of neck and
adjacent muscles on a neutral position, and describe how they are seen. It can be summarized
as the combination of turning to one side (torticollis), tilting or shifting to one side (laterocollis),
bending forward (antecollis) or backward (retrocollis). Shoulder elevation is frequently
accompanied.
Here are several methods to distinguish compensatory movements. The physicians have to
tell the patients “let the neck and shoulder relax as they move”, and make them walk repeat-
edly. Palpation of the candidate muscles is helpful in assessing whether they are hypertrophic
or contain bands. The features of dystonia such as task-specificity, overflow, and null-point
could also be important clues. Especially for tremulous CD, if a tremor diminishes at a specific
position, the muscles inducing that position would be affected by dystonia. Short-term follow-
up can reveal critical information. The effect of BoNT for CD is generally maximized within 2
or 3 weeks after injection. Therefore, early visits can provide information whether previous
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target sites were appropriate as well as whether the patient is a BoNT non-responder. The
dynamic progression of dystonia is another reason why follow-up is important.
4.1.2. Facial involuntary movements
Determining target sites in facial involuntary movements is relatively simple compared to CD.
Therefore, when BoNT is injected into the face, avoiding side effects is given much weight. The
face contains other important anatomical structures such as the eye balls, lacrimal ducts,
salivary glands, nerves, and vessels. The direction of the needle always must head away from
the eye balls. Two canaliculi per eye exist in the medial canthus. BoNT injection into the lower
canaliculus generally is avoided because it is believed to have a main role in transporting tears
to the lacrimal sac and nasolacrimal duct. When injecting into the masseter muscle, it is better
to preserve the lower posterior portion where the parotid gland is placed.
Asymmetry and ptosis should be considered. To prevent asymmetry, injections are often given
also on the contralateral side. To prevent ptosis, BoNT injections to the mid-portions of the
upper eyelid and frontalis area are avoided. Especially, when the orbicularis oculi is the target,
injection into the pretarsal area has stronger effects and less frequent ptosis than injections into
the preseptal area [14, 15].
4.1.3. Limb dystonia
Using overflow phenomenon and mirror movement is a good way to differentiate main
symptomatic spasms from compensatory ones [16]. If hand dystonia is too complex to
determine a target, an EMG-guided approach will be useful. However, it is not easy to inject
only into the real target site because the hands are comprised of small muscles for delicate
movements. And paralysis of specific muscle rather can cause great inconvenience in most
situations except when that specific task is performed.
4.2. Determining target volume
Once the target muscles for BoNT injection have been chosen, the next step is determining how
much BoNT and how many injection sites are required. The recommended volumes for several
target muscles are provided in the prescription information [3–5]. However, the response
varies from person to person and information for every possible indication is not included.
Thus, the injection volume and site should be individualized taking into consideration race,
sex, age, medical condition, etc.
The followings are additional helpful tips in determining the injection volume.
• For larger target muscles, a larger volume of BoNT is required.
• It is safer to apply a low dose first.
• Imagining the diffusion pattern of BoNT is important.
Borodic et al. [17] reported several important features for the BoNT/A diffusion pattern in the
longissimus dorsi of rabbits: the diffusion of BoNT/A occurred in a dose-dependent manner;
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the spread pattern in the injected muscle was more linear than in a remote muscle of the same
distance; lower doses did not affect a different muscle located 45 mm from the injection site
while higher doses diffused even into that muscle. This study supports the concept that
injection into multiple sites with lower doses could reduce side effects by preventing the
diffusion of BoNT, in other words its biological effect, to other muscles beyond the injection
site [18]. Therefore, Rosales et al. [19] recommended a “high potency, low dilution” of
BoNT/A for oromandibular, lingual, cranial, cervical, and distal limb dystonias, which are
small and localized targets. In contrast, A “low potency, high dilution” of BoNT/A is more
useful for big muscles.
4.3. Methods of botulinum toxin injection
The method of injection mainly depends on the anatomical features of target sites.
Superficial fat compartments are distributed throughout the entire face excluding the upper
eyelids, nose, and mouth [20]. Most facial muscles are located just beneath the skin and
subcutaneous fat, whereas peri-ocular and peri-oral areas have little fatty tissue. Facial skin is
relatively thin compared to the other parts. Especially, the skin thickness of the palpebral areas
is only around 0.5 mm. Therefore, when the orbicularis oculi or orbicularis oris muscle is the
target, the needle should be inserted horizontally to skin as much as possible although more
pain at the injection site is inevitable. Smoothing out skin wrinkles is important for easy
needling. Vesicle formation is also recommended in these areas because it seems to be helpful
in localizing the extent of chemo-denervation. For other facial muscles, the angle between
needle and skin needs to be set a little bit higher so that the needle can be inserted into a deeper
location. Another important consideration in facial muscle anatomy is that the facial muscles
have few muscle spindles except in jaw muscles. It refers that BoNT injections directly impact
on extrafusal muscle fibers in face.
On the other hand, neck and limb muscles are large and located more deeply. For effective
delivery of BoNT, a long needle inserted perpendicularly to the skin is necessary. This direction
of insertion is also good for reducing pain. Grasping and fixing muscles are essential for precise
targeting. Postures of activating relevant muscles and imaging- or EMG-guided methods may
be of great help to approach deep muscles. Before administering the BoNT solution, pulling
back is required to ascertain whether the needle reaches the target muscle or adjunctive vessel.
5. Conclusion
To provide the appropriate BoNT treatment, the practitioner should be well informed of the
etio-pathogenesis of disorders and the anatomy of the target area, as well as the action
mechanism of BoNT and methods of storage and injection. Patients must also understand that
BoNT treatment is just a way to relieve symptoms, and not treatment for underlying causes.
Repeated applications of BoNT are required because the effects last for 3 months on average.
Paradoxically, BoNT is a reversible and very safe toxin in terms of side effects. We hope that
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the guides of this chapter are very helpful in understanding and using BoNT in a clinical
setting.
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